BACKGROUND: Delayed correction of blood clotting times as measured by the International Normalized Ratio (INR) is associated with adverse outcomes among certain patients with warfarin-related major bleeding. However, there are limited data on the association between INR correction and mortality. OBJECTIVE: To assess factors associated with 30-day mortality and time to death in patients receiving fresh frozen plasma (FFP) for warfarin-associated major bleeding. METHODS: A retrospective database analysis was undertaken with electronic health record data from a large integrated health system. Patients met the following criteria: major hemorrhage diagnosis; INR ≥ 2 on the day before or day of receipt of FFP; and prescription fill for warfarin within 90 days. INR correction (defined as INR ≤ 1.3) was evaluated at the last available test 1 day following the start of FFP administration. Kaplan-Meier curves and Cox proportional hazards models were constructed to assess mortality. RESULTS: Four hundred and five patients met the selection criteria (mean age of 75 years, 54% male), and 67% remained uncorrected at 1 day following the start of FFP administration. Among all patients, 11% died within 30 days of hospital admission. An uncorrected INR was not associated with a higher risk of 30-day mortality for patients overall, but was statistically significant for the subgroup with intracranial hemorrhage (ICH) (adjusted odds ratio 2.55; 95% confidence interval 1.04-6.28). CONCLUSIONS: Among the subgroup of major bleeding patients with warfarin-associated ICH, those not correcting to either INR ≤ 1.3 or INR ≤ 1.5 with the use of FFP have an increased rate of mortality at 30 days.
BACKGROUND: Delayed correction of blood clotting times as measured by the International Normalized Ratio (INR) is associated with adverse outcomes among certain patients with warfarin-related major bleeding. However, there are limited data on the association between INR correction and mortality. OBJECTIVE: To assess factors associated with 30-day mortality and time to death in patients receiving fresh frozen plasma (FFP) for warfarin-associated major bleeding. METHODS: A retrospective database analysis was undertaken with electronic health record data from a large integrated health system. Patients met the following criteria: major hemorrhage diagnosis; INR ≥ 2 on the day before or day of receipt of FFP; and prescription fill for warfarin within 90 days. INR correction (defined as INR ≤ 1.3) was evaluated at the last available test 1 day following the start of FFP administration. Kaplan-Meier curves and Cox proportional hazards models were constructed to assess mortality. RESULTS: Four hundred and five patients met the selection criteria (mean age of 75 years, 54% male), and 67% remained uncorrected at 1 day following the start of FFP administration. Among all patients, 11% died within 30 days of hospital admission. An uncorrected INR was not associated with a higher risk of 30-day mortality for patients overall, but was statistically significant for the subgroup with intracranial hemorrhage (ICH) (adjusted odds ratio 2.55; 95% confidence interval 1.04-6.28). CONCLUSIONS: Among the subgroup of major bleedingpatients with warfarin-associated ICH, those not correcting to either INR ≤ 1.3 or INR ≤ 1.5 with the use of FFP have an increased rate of mortality at 30 days.
Authors: Murtaza Akhter; Andrea Morotti; Abigail Sara Cohen; Yuchiao Chang; Alison M Ayres; Kristin Schwab; Anand Viswanathan; Mahmut Edip Gurol; Christopher David Anderson; Steven Mark Greenberg; Jonathan Rosand; Joshua Norkin Goldstein Journal: Intern Emerg Med Date: 2017-06-01 Impact factor: 3.397
Authors: Peter Toth; Joost Jair van Veen; Kate Robinson; Rhona Murray Maclean; Kingsley Kevin Hampton; Stuart Laidlaw; Michael Makris Journal: Blood Transfus Date: 2012-10-10 Impact factor: 3.443
Authors: Karim Tazarourte; Bruno Riou; Benjamin Tremey; Charles-Marc Samama; Eric Vicaut; Bernard Vigué Journal: Crit Care Date: 2014-04-24 Impact factor: 9.097
Authors: Simon Bordeleau; Julien Poitras; Danièle Marceau; Carolle Breton; Pierre Beaupré; Patrick M Archambault Journal: BMC Health Serv Res Date: 2015-03-15 Impact factor: 2.655
Authors: Gorkem Sezgin; Andrew Georgiou; Rae-Anne Hardie; Ling Li; Lisa G Pont; Tony Badrick; Guilherme S Franco; Johanna I Westbrook; Natalie Rinehart; Adam McLeod; Christopher Pearce; Marianne Shearer; Robin Whyte; Elizabeth Deveny Journal: BMJ Open Date: 2018-11-13 Impact factor: 2.692